ENGIC 01 (PRODIGE 107)– COLOSOTO
A single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) in first-line treatment of patients non-eligible for a doublet/triplet chemotherapy with advanced unresectable KRAS G12C mutated colorectal adenocarcinoma
A single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) in first-line treatment of patients non-eligible for a doublet/triplet chemotherapy with advanced unresectable KRAS G12C mutated colorectal adenocarcinoma
Phase: Phase II clinical trials
Principal Investigator: Dott. Pietrantonio Filippo
Main Facility: Oncologia Medica Gastroenterologica
Drug: Panitumumab, 5-Fluorouracile, Sotorasib
Pathologies: Colorectal cancer (CRC)
ClinicalTrials.gov: Read the details about clinical trials
This is an open-label, non-randomised, single-arm first-line treatment study enrolling patients with locally advanced or unresectable metastatic colorectal cancer harbouring a KRAS G12C mutation. Participants receive treatment with panitumumab plus 5-fluorouracil every two weeks in combination with sotorasib daily.
The primary objective of this study is to assess progression-free survival at 8 months.
Last update: 14/07/2026